Table 5.

Clinical adverse events associated with rifampin use

	Courses, n (%) N=4279	Patient level, n (%) N=2500
Gastrointestinal
Necrotizing enterocolitis – medical	133 (3%)	64 (3%)
Necrotizing enterocolitis – surgical	41 (1%)	19 (1%)
Focal intestinal perforation	3 (0.07%)	1 (0.04%)
Neurologic
Intraventricular hemorrhage – grade III or IV	91 (2%)	36 (1%)
Seizure	132 (3%)	60 (2%)
Dermatologic
Rash	33 (1%)	15 (0.6%)
Pulmonary
Pulmonary hemorrhage	50 (1%)	22 (1%)
Any clinical adverse event	426 (10%)	197 (8%)